Clinical Trial Database

Clinical Trial News

Phase III

Merck's Ace Keytruda Impresses Again, Stuns in Phase III Lung Cancer Trial

Merck's Keytruda has done it again.

Novartis' Cosentyx Beats Johnson & Johnson’s Stelara in Head-to-Head Trial

The safety profile of Cosentyx was in line with the known safety profile.

MiMedx Announces First Patients Have Been Enrolled in the Phase III Clinical Trial of AmnioFix Injectable in Patients Wi...

Top-line results from this study are expected in the second half of 2019.

Centrexion Therapeutics Announces Fast Track Designation Granted by FDA to CNTX-4975 for Treatment of Knee Osteoarthriti...

CNTX-4975, Centrexion’s Phase 3 ready lead therapy, is a synthetic, ultra-pure injection of trans-capsaicin designed to be injected directly into the painful joint to provide rapid and durable pain relief.

Athenex Receives Positive Feedback From FDA on the Design of Phase III Clinical Trial for Oraxol

The Oraxol Phase III clinical study is a randomized controlled international clinical trial investigating the superiority of Oraxol over intravenous paclitaxel in the treatment of patients with metastatic breast cancer.

Phase I

Gamida Cell Announces Initiation of a Phase I Study of NAM-NK Cells Immunotherapy Program for Non-Hodgkin Lymphoma and Multiple Myeloma

1/16/2018

AveXis Announces Expanded Clinical Development Program for AVXS-101 in Spinal Muscular Atrophy

Gamida Cell today announced the initiation of a phase I study evaluating its proprietary NAM-expanded natural killer cells (NAM-NK Cells) in patients with relapsed or refractory CD20+ non-Hodgkin lymphoma (NHL) and multiple myeloma.

Saniona Initiates Phase I Study With New Tesomet Tablet

Additionally, the company announced the first patient has been dosed in the Phase 1 trial of AVXS-101 in SMA Type 2.

Leap Therapeutics Announces First Patient Dosed with TRX518 Combination Therapy in Advanced Solid Tumors Trial

The trial will comprise a total of 60 volunteers. Saniona expects to report results from the trial in the second quarter 2018.

Cellect Announces Opening of a Second Clinical Trial Site and Approval from Safety Board (DSMB) for Dose Escalation

The TRX518-003 study is a multipart study evaluating TRX518 as a monotherapy and in combination with gemcitabine, KEYTRUDA, or Opdivo in patients with advanced solid tumor malignancies.

Latest Updates from FDA DB

UVADEX

Labeling

RIFATER

Labeling

RIFADIN

Labeling

RIFADIN

Labeling

COARTEM

Labeling

ERAXIS

Labeling

ERAXIS

Labeling

NOXAFIL

Labeling

DOCETAXEL

Labeling

DOCETAXEL

Labeling